105 related articles for article (PubMed ID: 19649633)
1. Contribution of dihydropyrimidinase gene alterations to the development of serious toxicity in fluoropyrimidine-treated cancer patients.
Fidlerova J; Kleiblova P; Bilek M; Kormunda S; Formankova Z; Novotny J; Kleibl Z
Cancer Chemother Pharmacol; 2010 Mar; 65(4):661-9. PubMed ID: 19649633
[TBL] [Abstract][Full Text] [Related]
2. Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity.
Kummer D; Froehlich TK; Joerger M; Aebi S; Sistonen J; Amstutz U; Largiadèr CR
Pharmacogenomics; 2015; 16(12):1367-77. PubMed ID: 26244261
[TBL] [Abstract][Full Text] [Related]
3. Lack of large intragenic rearrangements in dihydropyrimidine dehydrogenase (DPYD) gene in fluoropyrimidine-treated patients with high-grade toxicity.
Ticha I; Kleiblova P; Fidlerova J; Novotny J; Pohlreich P; Kleibl Z
Cancer Chemother Pharmacol; 2009 Aug; 64(3):615-8. PubMed ID: 19288105
[TBL] [Abstract][Full Text] [Related]
4. Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects.
Gross E; Ullrich T; Seck K; Mueller V; de Wit M; von Schilling C; Meindl A; Schmitt M; Kiechle M
Hum Mutat; 2003 Dec; 22(6):498. PubMed ID: 14635116
[TBL] [Abstract][Full Text] [Related]
5. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
Schwab M; Zanger UM; Marx C; Schaeffeler E; Klein K; Dippon J; Kerb R; Blievernicht J; Fischer J; Hofmann U; Bokemeyer C; Eichelbaum M;
J Clin Oncol; 2008 May; 26(13):2131-8. PubMed ID: 18299612
[TBL] [Abstract][Full Text] [Related]
6. Two cases of 5-fluorouracil toxicity linked with gene variants in the DPYD gene.
Ofverholm A; Arkblad E; Skrtic S; Albertsson P; Shubbar E; Enerbäck C
Clin Biochem; 2010 Feb; 43(3):331-4. PubMed ID: 19822137
[TBL] [Abstract][Full Text] [Related]
7. Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene.
van Kuilenburg AB; Haasjes J; Richel DJ; Zoetekouw L; Van Lenthe H; De Abreu RA; Maring JG; Vreken P; van Gennip AH
Clin Cancer Res; 2000 Dec; 6(12):4705-12. PubMed ID: 11156223
[TBL] [Abstract][Full Text] [Related]
8. Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism.
Thomas HR; Ezzeldin HH; Guarcello V; Mattison LK; Fridley BL; Diasio RB
Pharmacogenet Genomics; 2007 Nov; 17(11):973-87. PubMed ID: 18075467
[TBL] [Abstract][Full Text] [Related]
9. Common dihydropyrimidinase ( DPYS ) genetic variations do not predict fluoropyrimidine-related chemotherapy toxicity in a Canadian cohort.
Medwid SJ; Mailloux JL; Wigle TJ; Kim RB
Pharmacogenet Genomics; 2024 Apr; 34(3):83-87. PubMed ID: 38215018
[TBL] [Abstract][Full Text] [Related]
10. Contribution of the β-ureidopropionase (UPB1) gene alterations to the development of fluoropyrimidine-related toxicity.
Fidlerova J; Kleiblova P; Kormunda S; Novotny J; Kleibl Z
Pharmacol Rep; 2012; 64(5):1234-42. PubMed ID: 23238479
[TBL] [Abstract][Full Text] [Related]
11. Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism.
Thomas HR; Ezzeldin HH; Guarcello V; Mattison LK; Fridley BL; Diasio RB
Pharmacogenet Genomics; 2008 Jan; 18(1):25-35. PubMed ID: 18216719
[TBL] [Abstract][Full Text] [Related]
12. Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity.
van Kuilenburg AB; Meinsma R; Zonnenberg BA; Zoetekouw L; Baas F; Matsuda K; Tamaki N; van Gennip AH
Clin Cancer Res; 2003 Oct; 9(12):4363-7. PubMed ID: 14555507
[TBL] [Abstract][Full Text] [Related]
13. [Pharmacogenetics in oncology: 5-fluorouracil and the dihydropyrimidine dehydrogenase].
Lazar A; Jetter A
Dtsch Med Wochenschr; 2008 Jul; 133(28-29):1501-4. PubMed ID: 18597209
[TBL] [Abstract][Full Text] [Related]
14. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.
Ezzeldin H; Johnson MR; Okamoto Y; Diasio R
Clin Cancer Res; 2003 Aug; 9(8):3021-8. PubMed ID: 12912951
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls.
Raida M; Schwabe W; Häusler P; Van Kuilenburg AB; Van Gennip AH; Behnke D; Höffken K
Clin Cancer Res; 2001 Sep; 7(9):2832-9. PubMed ID: 11555601
[TBL] [Abstract][Full Text] [Related]
16. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity.
Bocci G; Barbara C; Vannozzi F; Di Paolo A; Melosi A; Barsanti G; Allegrini G; Falcone A; Del Tacca M; Danesi R
Clin Pharmacol Ther; 2006 Oct; 80(4):384-95. PubMed ID: 17015056
[TBL] [Abstract][Full Text] [Related]
17. A study on the association of cytochrome-P450 1A1 polymorphism and breast cancer risk in north Indian women.
Singh V; Rastogi N; Sinha A; Kumar A; Mathur N; Singh MP
Breast Cancer Res Treat; 2007 Jan; 101(1):73-81. PubMed ID: 16807674
[TBL] [Abstract][Full Text] [Related]
18. The burden of rare variants in DPYS gene is a novel predictor of the risk of developing severe fluoropyrimidine-related toxicity.
De Mattia E; Polesel J; Silvestri M; Roncato R; Scarabel L; Calza S; Spina M; Puglisi F; Toffoli G; Cecchin E
Hum Genomics; 2023 Nov; 17(1):99. PubMed ID: 37946254
[TBL] [Abstract][Full Text] [Related]
19. Impact of DPYD, DPYS, and UPB1 gene variations on severe drug-related toxicity in patients with cancer.
Yokoi K; Nakajima Y; Matsuoka H; Shinkai Y; Ishihara T; Maeda Y; Kato T; Katsuno H; Masumori K; Kawada K; Yoshikawa T; Ito T; Kurahashi H
Cancer Sci; 2020 Sep; 111(9):3359-3366. PubMed ID: 32619063
[TBL] [Abstract][Full Text] [Related]
20. [Dihydropyrimidine dehydrogenase activity and its genetic aberrations].
Ogura K
Gan To Kagaku Ryoho; 2006 Aug; 33(8):1041-8. PubMed ID: 16912518
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
